- Home
- Publications
- Publication Search
- Publication Details
Title
Evolving Role of Immunotherapy in Small Cell Lung Cancer
Authors
Keywords
SCLC, Small cell lung cancer, Immunotherapy, Atezolizumab, Durvalumab
Journal
SEMINARS IN CANCER BIOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-02-19
DOI
10.1016/j.semcancer.2022.02.021
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
- (2021) Carl M. Gay et al. CANCER CELL
- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
- (2021) Stephen V. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆
- (2021) D.R. Spigel et al. ANNALS OF ONCOLOGY
- Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
- (2021) Taofeek K. Owonikoko et al. JOURNAL OF CLINICAL ONCOLOGY
- OA11.06 IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer
- (2021) M. Reck et al. Journal of Thoracic Oncology
- Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy – Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
- (2021) S. Peters et al. ANNALS OF ONCOLOGY
- VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo)
- (2021) S.V. Liu et al. ANNALS OF ONCOLOGY
- Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).
- (2021) Taofeek K. Owonikoko et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC
- (2021) B.C. Cho et al. ANNALS OF ONCOLOGY
- Immunotherapeutic approaches for small-cell lung cancer
- (2020) Wade T. Iams et al. Nature Reviews Clinical Oncology
- Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.
- (2020) Ticiana Leal et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
- (2020) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
- (2020) José Trigo et al. LANCET ONCOLOGY
- LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
- (2020) J.W. Goldman et al. ANNALS OF ONCOLOGY
- TIGIT in cancer immunotherapy
- (2020) Joe-Marc Chauvin et al. Journal for ImmunoTherapy of Cancer
- The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
- (2020) Niamh Coleman et al. BRITISH JOURNAL OF CANCER
- Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
- (2020) Jonathan W Goldman et al. LANCET ONCOLOGY
- A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial
- (2019) Jean-Louis Pujol et al. Journal of Thoracic Oncology
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. CANCER CELL
- Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
- (2019) Neal E. Ready et al. Journal of Thoracic Oncology
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
- (2019) Hyun Cheol Chung et al. Journal of Thoracic Oncology
- Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).
- (2018) Jonathan Wade Goldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
- (2018) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer
- (2018) Yanis Boumber Journal of Thoracic Disease
- 1665PDPreliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study
- (2018) I Bondarenko et al. ANNALS OF ONCOLOGY
- Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
- (2018) Neal Ready et al. Journal of Thoracic Oncology
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome
- (2017) Paul Maddison et al. NEUROLOGY
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
- (2016) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Phosphatase PP2A is requisite for the function of regulatory T cells
- (2016) Sokratis A Apostolidis et al. NATURE IMMUNOLOGY
- PD-L1 expression in small cell lung cancer
- (2015) Takefumi Komiya et al. EUROPEAN JOURNAL OF CANCER
- Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
- (2015) Hidenobu Ishii et al. Journal of Thoracic Oncology
- The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+T cell responses
- (2015) Robert J Johnston et al. OncoImmunology
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- (2012) Lauren Averett Byers et al. Cancer Discovery
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now